Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to Ba3 from B1 and Probability of Default Rating ("PDR") to Ba3-PD from B1-PD. Concurrently, we affirmed the Ba2 rating on Insulet's senior secured term loan and assigned a Ba2 rating to Insulet's new ...
Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...
Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to B1 from B2 and Probability of Default Rating ("PDR") to B1-PD from B2-PD. Concurrently, we affirmed the Ba2 ratings on Insulet's senior secured credit facilities, including the senior secured term l...
Moody's Investors Service ("Moody's") affirmed the ratings of Insulet Corporation, ("Insulet") including the Corporate Family Rating ("CFR") at B2, and Probability of Default Rating ("PDR") at B2-PD. At the same time, Moody's upgraded Insulet's ratings on the senior secured term loan and senior secu...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
The general evaluation of INSULET (US), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 15, 2022, the closing price was USD...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Rating Action: Moody's assigns B2 CFR to Insulet; Ba3 sr. secured. Global Credit Research- 19 Apr 2021. New York, April 19, 2021-- Moody's Investors Service assigned ratings to Insulet Corporation including a B2 Corporate Family Rating, a B2-PD Probability of Default Rating, a Ba3 senior secured rating and an SGL-1 Speculative Grade Liquidity Rating.
S&P 500 Testing Key Resistance As we have outlined in recent weeks, our base case continues to be for near-term consolidation while the market is in a “wait-and-see†phase as it relates to states re-opening. The S&P 500 is again testing key resistance at the 61.8% Fibonacci retracement level of 2934.49 and also the 2950-3000 level we previously identified. We continue to have concerns that lead us to believe the market is not yet out of the woods, however these concerns are counterbalanced ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.